Daxor Corporation (NASDAQ:DXR - Get Free Report) was the target of a significant decline in short interest in February. As of February 13th, there was short interest totaling 3,761 shares, a decline of 44.0% from the January 29th total of 6,713 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,480 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily trading volume, of 6,480 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Lake Street Capital assumed coverage on Daxor in a report on Wednesday, February 11th. They set a "buy" rating for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Daxor in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.

Check Out Our Latest Stock Report on Daxor

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. acquired a new stake in Daxor Corporation (NASDAQ:DXR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,750 shares of the company's stock, valued at approximately $86,000. Osaic Holdings Inc. owned 0.18% of Daxor at the end of the most recent quarter. Hedge funds and other institutional investors own 1.34% of the company's stock.

Daxor Stock Performance

Daxor stock traded down $0.09 during trading on Friday, reaching $11.86. 517 shares of the company were exchanged, compared to its average volume of 5,659. The stock's 50 day simple moving average is $13.10 and its two-hundred day simple moving average is $12.62. Daxor has a 52-week low of $7.10 and a 52-week high of $14.76.

About Daxor

(Get Free Report)

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company's core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient's fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.

Further Reading

• Five stocks we like better than Daxor
• 3 Signs You May Want to Switch Financial Advisors
• Unlocked: Elon Musk’s Next Big IPO
• Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
• 1,500 Banks Just Handed the Fed Your Bank Account
• Your name isn't on our protected list yet

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Daxor Right Now?

Before you consider Daxor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daxor wasn't on the list.

While Daxor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here